Bifogade filer
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Increased organic growth in both business areas
AddLife´s year-end report for Q4 2022 is now available online at the company website. The year-end report can be downloaded in pdf version. Visit https://reports-en.add.life/year-end-report-q4-2022
1 OCTOBER – 31 DECEMBER 2022 (3 MONTHS)
- Net sales increased by 9 percent to SEK 2,326m (2,131), of which acquired growth amounted to 12 percent. The COVID-19 related net sales decreased by 82 percent. The organic growth, excluding net sales related to COVID-19, was 6 percent.
- EBITA amounted to SEK 258m (329), corresponding to an EBITA-margin of 11.1 percent (15.5).
- Profit after tax amounted to SEK 62m (178).
- Earnings per share amounted to SEK 0.50 (1.46).
- Cash flow from operating activities amounted to SEK 351m (393).
1 JANUARY – 31 DECEMBER 2022 (12 MONTHS)
- Net sales increased by 14 percent to SEK 9,084m (7,993), of which acquired growth amounted to 22 percent. The COVID-19 related net sales decreased by 62 percent. The organic growth, excluding net sales related to COVID-19, was 4 percent.
- EBITA amounted to SEK 1,221m (1,273), corresponding to an EBITA-margin of 13.4 percent (15.9). EBITA includes a reversed contingent consideration of SEK 101m, excluding this, EBITA margin amounted to 12.3 percent.
- Profit after tax amounted to SEK 483m (721).
- Earnings per share amounted to SEK 3.96 (6.03).
- Cash flow from operating activities amounted to SEK 909m (1,010).
- The equity ratio was 38 percent (40).
- Return on working capital (P/WC) amounted to 61 percent (95).
- During the year, five acquisitions were completed. The acquisitions are expected to contribute with annual net sales of approximately SEK 850m.
- The Board of directors proposes a dividend of SEK 1.20 per share.
Stockholm, February 2, 2023
AddLife AB (publ)
For more information, contact;
Fredrik Dalborg, CEO, fredrik.dalborg@add.life, +46 70 516 09 01
Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22
www.add.life
Teleconference
Investors, analysts and the media are invited to a teleconference at which CEO Fredrik Dalborg and CFO Christina Rubenhag will present the year-end report. The presentation will be given in English and take about 20 minutes. after which there will be an opportunity to ask questions. The meeting will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.
The teleconference will be at 10 a.m. CET on February 2, 2023
If you wish to participate via teleconference, please follow this link>>
Or call in (only sound) +46 8 505 376 58 Conference-ID: 427 903 522#
The presentation is also available on AddLife YouTube >>
AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors, mainly in the Nordic region and rest of Europe. AddLife has about 2,200 employees in some 85 operating subsidiaries. The Group currently has net sales of approximately SEK 9 billion. AddLife shares are listed on Nasdaq Stockholm.
This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at February 2, 2023 at 07:45 a.m. CET.